Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

PURPOSE: Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and are approved for the treatment of patients with KRAS wild-type meta-static colorectal cancer. There are no data that describe the activity of panitumumab in patients with progress...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wadlow, Raymond C., Hezel, Aram F., Abrams, Thomas A., Blaszkowsky, Lawrence S., Fuchs, Charles S., Kulke, Matthew H., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Szymonifka, Jackie, Wolpin, Brian M., Zhu, Andrew X., Clark, Jeffrey W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2012
Soggetti:
Clinical Trial Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267814/
https://ncbi.nlm.nih.gov/pubmed/22210091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0452
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi